Cell therapeutics company Cyanata (ASX:CYP) has received the greenlight from British medical authority MHRA to begin the company’s Phase 2 clinical trial of its CYP-002 product.
The treatment uses mesenchymal stem cell technology to treat patients with crucial limb ischaemia.
This is a condition that affects patients with diabetes, obesity, high blood pressure & smokers.
According to research, the demand for CLI treatment is forecast to reach $5.4 billion by 2025.
Preclinical research has shown that Cynata’s project led to higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis, and limb loss.
The company intends to operate the clinical trial at multiple facilities in the UK and Australia.
Shares in Cynata Therapeutics (ASX:CYP) are trading 5 per cent higher at $1.26.